Identification of Modifier Genes in a Mouse Model of Gaucher Disease

Cell Reports

Volumn 16, Issue 10, 2016, Pages 2546-2553

  Klein, Andrés D ^a   Ferreira, Natalia Santos ^a   Ben Dor, Shifra ^a   Duan, Jingjing ^b   Hardy, John ^c   Cox, Timothy M ^d   Merrill, Alfred H ^b   Futerman, Anthony H ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCOSIDASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; CONDURITOL EPOXIDE; INOSITOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2B NMDA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME SUBSTRATE; GAUCHER DISEASE; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; LIFESPAN; MALE; MODIFIER GENE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETICS; INBRED MOUSE STRAIN; INJECTION; LONGEVITY; METABOLISM; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; GAUCHER DISEASE; GENES, MODIFIER; GENOME-WIDE ASSOCIATION STUDY; INJECTIONS; INOSITOL; LONGEVITY; MICE, INBRED STRAINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 85006401138     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.07.085     Document Type: Article

References (43)

1. Aarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., Londos, E., Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8 (2009), 613–618.
2. Altarescu, G., Phillips, M., Foldes, A.J., Elstein, D., Zimran, A., Mates, M., The interleukin-6 promoter polymorphism in Gaucher disease: a new modifier gene?. QJM 96 (2003), 575–578.
3. Altarescu, G., Zimran, A., Michelakakis, H., Elstein, D., TNF-alpha levels and TNF-alpha gene polymorphism in type I Gaucher disease. Cytokine 31 (2005), 149–152.
4. Alvarez, A.R., Klein, A., Castro, J., Cancino, G.I., Amigo, J., Mosqueira, M., Vargas, L.M., Yévenes, L.F., Bronfman, F.C., Zanlungo, S., Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB J. 22 (2008), 3617–3627.
5. Argmann, C.A., Houten, S.M., Zhu, J., Schadt, E.E., A next generation multiscale view of inborn errors of metabolism. Cell Metab. 23 (2016), 13–26.
6. Beutler, E., West, C., Polymorphisms in glucosylceramide (glucocerebroside) synthase and the Gaucher disease phenotype. Isr. Med. Assoc. J. 4 (2002), 986–988.
7. Bland, J.M., Altman, D.G., Multiple significance tests: the Bonferroni method. BMJ, 310, 1995, 170.
8. Crowley, J.J., Kim, Y., Szatkiewicz, J.P., Pratt, A.L., Quackenbush, C.R., Adkins, D.E., van den Oord, E., Bogue, M.A., Yang, H., Wang, W., et al. Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm. Genome 23 (2012), 322–335.
9. Danysz, W., Parsons, C.G., Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 50 (1998), 597–664.
10. Dekker, N., Voorn-Brouwer, T., Verhoek, M., Wennekes, T., Narayan, R.S., Speijer, D., Hollak, C.E.M., Overkleeft, H.S., Boot, R.G., Aerts, J.M.F.G., The cytosolic β-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation. Blood Cells Mol. Dis. 46 (2011), 19–26.
11. Enquist, I.B., Lo Bianco, C., Ooka, A., Nilsson, E., Månsson, J.-E., Ehinger, M., Richter, J., Brady, R.O., Kirik, D., Karlsson, S., Murine models of acute neuronopathic Gaucher disease. Proc. Natl. Acad. Sci. USA 104 (2007), 17483–17488.
12. Farfel-Becker, T., Vitner, E.B., Futerman, A.H., Animal models for Gaucher disease research. Dis. Model. Mech. 4 (2011), 746–752.
13. Farfel-Becker, T., Vitner, E.B., Pressey, S.N.R., Eilam, R., Cooper, J.D., Futerman, A.H., Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum. Mol. Genet. 20 (2011), 1375–1386.
14. Farfel-Becker, T., Vitner, E.B., Kelly, S.L., Bame, J.R., Duan, J., Shinder, V., Merrill, A.H. Jr., Dobrenis, K., Futerman, A.H., Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum. Mol. Genet. 23 (2014), 843–854.
15. Finn, R.D., Coggill, P., Eberhardt, R.Y., Eddy, S.R., Mistry, J., Mitchell, A.L., Potter, S.C., Punta, M., Qureshi, M., Sangrador-Vegas, A., et al. The Pfam protein families database: towards a more sustainable future. Nucleic Acids Res. 44:D1 (2016), D279–D285.
16. Grabowski, G.A., Petsko, G.A., Kolodny, E.H., Gaucher disease. Valle, D., Beaudet, A.L., Vogelstein, B., Kinzler, K.W., Antonarakis, S.E., Ballabio, A., Gibson, K.M., Mitchell, G., (eds.) The Online Metabolic and Molecular Bases of Inherited Disease, 2013, McGraw-Hill Medical.
17. Greenwood, A., Elstein, D., Zimran, A., Altarescu, G., Effect of vitamin D receptor (VDR) genotypes on the risk for osteoporosis in type 1 Gaucher disease. Clin. Rheumatol. 29 (2010), 1037–1041.
18. Gropman, A.L., Adams, D.R., Atypical patterns of inheritance. Semin. Pediatr. Neurol. 14 (2007), 34–45.
19. Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 366 (2012), 893–903.
20. Kang, H.M., Zaitlen, N.A., Wade, C.M., Kirby, A., Heckerman, D., Daly, M.J., Eskin, E., Efficient control of population structure in model organism association mapping. Genetics 178 (2008), 1709–1723.
21. Kirby, A., Kang, H.M., Wade, C.M., Cotsapas, C., Kostem, E., Han, B., Furlotte, N., Kang, E.Y., Rivas, M., Bogue, M.A., et al. Fine mapping in 94 inbred mouse strains using a high-density haplotype resource. Genetics 185 (2010), 1081–1095.
22. Korkotian, E., Schwarz, A., Pelled, D., Schwarzmann, G., Segal, M., Futerman, A.H., Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem. 274 (1999), 21673–21678.
23. Kovács, A.D., Pearce, D.A., Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender. Dis. Model. Mech. 8 (2015), 351–361.
24. Moy, S.S., Nadler, J.J., Young, N.B., Perez, A., Holloway, L.P., Barbaro, R.P., Barbaro, J.R., Wilson, L.M., Threadgill, D.W., Lauder, J.M., et al. Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behav. Brain Res. 176 (2007), 4–20.
25. Nalls, M.A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I.G., Chinnery, P.F., Morris, C.M., Theuns, J., Crosiers, D., Cras, P., et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70 (2013), 727–735.
26. Pan, Y., Chen, J., Guo, H., Ou, J., Peng, Y., Liu, Q., Shen, Y., Shi, L., Liu, Y., Xiong, Z., et al. Association of genetic variants of GRIN2B with autism. Sci. Rep., 5, 2015, 8296.
27. Parks, B.W., Nam, E., Org, E., Kostem, E., Norheim, F., Hui, S.T., Pan, C., Civelek, M., Rau, C.D., Bennett, B.J., et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab. 17 (2013), 141–152.
28. Parra, J., Klein, A.D., Castro, J., Morales, M.G., Mosqueira, M., Valencia, I., Cortés, V., Rigotti, A., Zanlungo, S., Npc1 deficiency in the C57BL/6J genetic background enhances Niemann-Pick disease type C spleen pathology. Biochem. Biophys. Res. Commun. 413 (2011), 400–406.
29. Pelled, D., Trajkovic-Bodennec, S., Lloyd-Evans, E., Sidransky, E., Schiffmann, R., Futerman, A.H., Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol. Dis. 18 (2005), 83–88.
30. Peters, M.J., Joehanes, R., Pilling, L.C., Schurmann, C., Conneely, K.N., Powell, J., Reinmaa, E., Sutphin, G.L., Zhernakova, A., Schramm, K., et al., NABEC/UKBEC Consortium. The transcriptional landscape of age in human peripheral blood. Nat. Commun., 6, 2015, 8570.
31. Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998), 2085–2088.
32. Rasmussen, A.L., Okumura, A., Ferris, M.T., Green, R., Feldmann, F., Kelly, S.M., Scott, D.P., Safronetz, D., Haddock, E., LaCasse, R., et al. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 346 (2014), 987–991.
33. Schiffmann, R., Vellodi, A., Neuronopathic Gaucher disease. Futerman, A.H., Zimran, A., (eds.) Gaucher Disease, 2007, Taylor and Francis Group, Boca Raton, FL, 175–196.
34. Specht, C.G., Schoepfer, R., Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci., 2, 2001, 11.
35. Tu, S., Shin, Y., Zago, W.M., States, B.A., Eroshkin, A., Lipton, S.A., Tong, G.G., Nakanishi, N., Takusan: a large gene family that regulates synaptic activity. Neuron 55 (2007), 69–85.
36. Turner, S.D., qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. bioRxiv, 2014, 1–2, 10.1101/005165.
37. Vahabzadeh, A., Landino, S.M., Finger, B.C., Carlezon, W.A. Jr., McDougle, C.J., Neural targets in the study and treatment of social cognition in autism spectrum disorder. Handbook Exp. Pharmacol. 228 (2015), 309–334.
38. Vardi, A., Zigdon, H., Meshcheriakova, A., Klein, A.D., Yaacobi, C., Eilam, R., Kenwood, B.M., Rahim, A.A., Massaro, G., Merrill, A.H. Jr., et al. Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. J. Pathol. 239 (2016), 496–509.
39. Velayati, A., DePaolo, J., Gupta, N., Choi, J.H., Moaven, N., Westbroek, W., Goker-Alpan, O., Goldin, E., Stubblefield, B.K., Kolodny, E., et al. A mutation in SCARB2 is a modifier in Gaucher disease. Hum. Mutat. 32 (2011), 1232–1238.
40. Vitner, E.B., Salomon, R., Farfel-Becker, T., Meshcheriakova, A., Ali, M., Klein, A.D., Platt, F.M., Cox, T.M., Futerman, A.H., RIPK3 as a potential therapeutic target for Gaucher's disease. Nat. Med. 20 (2014), 204–208.
41. Vitner, E.B., Farfel-Becker, T., Ferreira, N.S., Leshkowitz, D., Sharma, P., Lang, K.S., Futerman, A.H., Induction of the type I interferon response in neurological forms of Gaucher disease. J. Neuroinflammation, 13, 2016, 104.
42. Yuan, R., Tsaih, S.W., Petkova, S.B., Marin de Evsikova, C., Xing, S., Marion, M.A., Bogue, M.A., Mills, K.D., Peters, L.L., Bult, C.J., et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell 8 (2009), 277–287.
43. Zhang, C.K., Stein, P.B., Liu, J., Wang, Z., Yang, R., Cho, J.H., Gregersen, P.K., Aerts, J.M.F.G., Zhao, H., Pastores, G.M., Mistry, P.K., Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. Am. J. Hematol. 87 (2012), 377–383.